Evidence map›Paper›PMID 30854484›Full record

ArticleCommunications biology2019

Targeted drug delivery via caveolae-associated protein PV1 improves lung fibrosis.

Gabriela M Marchetti, Timothy J Burwell, Norman C Peterson, Jennifer A Cann, Richard N Hanna, Qing Li, Emily L Ongstad, Jonathan T Boyd, Maureen A Kennedy, Weiguang Zhao and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Equip your vehicle for the right terrain: Using features of local pathology to guide engineering of targeted drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Gabriela M MarchettiAntibody Discovery & Protein Engineering, MedImmune, Gaithersburg, MD, 20878, USA.
Timothy J BurwellRespiratory, Inflammation and Autoimmune Diseases, MedImmune, Gaithersburg, MD, 20878, USA.
Norman C PetersonTranslational Sciences, MedImmune, Gaithersburg, MD, 20878, USA.
Jennifer A CannPathology, MedImmune, Gaithersburg, MD, 20878, USA.
Richard N HannaRespiratory, Inflammation and Autoimmune Diseases, MedImmune, Gaithersburg, MD, 20878, USA.
Qing LiAntibody Discovery & Protein Engineering, MedImmune, Gaithersburg, MD, 20878, USA.
Emily L OngstadCardiovascular & Metabolic Diseases, MedImmune, Gaithersburg, MD, 20878, USA.
Jonathan T BoydMicrobial Sciences, MedImmune, Gaithersburg, MD, 20878, USA.
Maureen A KennedyPathology, MedImmune, Gaithersburg, MD, 20878, USA.
Weiguang ZhaoPathology, MedImmune, Gaithersburg, MD, 20878, USA.
Keith W RickertAntibody Discovery & Protein Engineering, MedImmune, Gaithersburg, MD, 20878, USA.
Joseph S GrimsbyCardiovascular & Metabolic Diseases, MedImmune, Gaithersburg, MD, 20878, USA.
William F Dall'AcquaAntibody Discovery & Protein Engineering, MedImmune, Gaithersburg, MD, 20878, USA.
Herren WuAntibody Discovery & Protein Engineering, MedImmune, Gaithersburg, MD, 20878, USA.
Ping TsuiAntibody Discovery & Protein Engineering, MedImmune, Gaithersburg, MD, 20878, USA.
M Jack BorrokAntibody Discovery & Protein Engineering, MedImmune, Gaithersburg, MD, 20878, USA. borrokm@medimmune.com.
Ruchi GuptaCardiovascular & Metabolic Diseases, MedImmune, Gaithersburg, MD, 20878, USA.
AstraZeneca (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic administration of bio-therapeutics can result in only a fraction of drug reaching targeted tissues, with the majority of drug being distributed to tissues irrelevant to the drug's site of action. Targeted delivery to specific organs may allow for greater accumulation, better efficacy, and improved safety. We investigated how targeting plasmalemma vesicle-associated protein (PV1), a protein found in the endothelial caveolae of lungs and kidneys, can promote accumulation in these organs. Using ex vivo fluorescence imaging, we show that intravenously administered αPV1 antibodies localize to mouse lungs and kidneys. In a bleomycin-induced idiopathic pulmonary fibrosis (IPF) mouse model, αPV1 conjugated to Prostaglandin E

Indexed as

Drug CarriersDrug Delivery SystemsAnimalsBiomarkersBleomycinDinoprostoneDisease Models, AnimalGene ExpressionHumansIdiopathic Pulmonary FibrosisImmunohistochemistryKidneyLungMembrane ProteinsMiceBiomarkersBleomycinDinoprostoneDrug CarriersMembrane ProteinsPlvap protein, mouse

Identifiers

PMID30854484
PMCPMC6405929
OpenAlexW2919549209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.